secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001193125-23-082785
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Corvus terminates ATM equity programs with Jefferies
----------------------------------------------------

- Terminated 2020 Sales Agreement (up to $50M) and 2021 Sales Agreement (up to $40M) with Jefferies LLC effective March 28, 2023.
- Both at-the-market offering programs are no longer available for use.
- No reason for termination provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000119312523082785/0001193125-23-082785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000119312523082785/d483536d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-082785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer